Jazz Pharmaceuticals (JAZZ) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

• 5/6/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $239.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $220.00 to $275.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals was given a new $252.00 price target by Robert W. Baird.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $225.00 to $234.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $195.00 to $258.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $250.00 to $265.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Jazz Pharmaceuticals had its price target raised by Leerink Partners from $215.00 to $225.00. They now have an “outperform” rating on the stock.
• 4/20/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $224.00 to $225.00. They now have an “overweight” rating on the stock.
• 4/10/2026 – Jazz Pharmaceuticals is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $227.00 price target on the stock.
• 4/9/2026 – Jazz Pharmaceuticals was upgraded by Raymond James Financial, Inc. to “moderate buy”.
• 3/27/2026 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 3/25/2026 – Jazz Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/19/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an “overweight” rating on the stock.
• 3/9/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by Barclays PLC. They now have a $224.00 price target on the stock.

Insider Activity

In related news, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,015 shares of company stock valued at $14,180,486 in the last three months. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.